Psoriatic arthritis (PsA) and rheumatoid arthritis (RA) are both chronic inflammatory conditions that attack the joints, but they differ in which joints they target, how they show up on blood tests, and what other parts of the body they affect. The distinction matters because each condition responds best to different treatment strategies, and getting the right diagnosis early can prevent lasting joint damage.
Which Joints Are Affected
The most reliable way to tell these two conditions apart is by looking at the pattern of joint involvement. RA is predominantly symmetric, meaning it tends to hit the same joints on both sides of the body at the same time. If your right wrist is inflamed, your left wrist likely is too. PsA, on the other hand, is often asymmetric, sometimes affecting one knee or a few fingers on one hand while the other side stays quiet.
The specific joints involved also differ. RA typically targets the wrists, knuckles, and the middle joints of the fingers, along with larger joints like the shoulders, elbows, knees, and ankles. PsA can affect those same areas, but it has a strong tendency to involve the joints closest to the fingertips and toenails, known as the distal joints. Changes in these distal joints are found almost exclusively in PsA and rarely in RA.
PsA can also attack the spine and the sacroiliac joints at the base of the spine, which is why it’s classified within a broader family of diseases called spondyloarthritis. RA does not typically involve the lower spine, though it does affect the cervical spine (the neck area) in up to 80% of patients over time.
Dactylitis and Enthesitis: PsA’s Signature Features
Two hallmark features help distinguish PsA from RA. The first is dactylitis, sometimes called “sausage fingers” or “sausage toes.” This is uniform swelling of an entire finger or toe, so puffy that you can no longer tell where individual joint swelling begins or ends. About 50% of people with PsA develop dactylitis at some point. It does not occur in RA.
The second is enthesitis, which is inflammation where tendons and ligaments attach to bone. Common spots include the Achilles tendon, the bottom of the heel, and the area around the kneecap. Around 35% of PsA patients experience enthesitis. While tendon pain can occur with other conditions, its frequency and pattern in PsA is a key diagnostic clue.
Skin and Nail Changes
Most people with PsA either have psoriasis already or develop it over time. The skin disease usually appears first, sometimes years or even decades before joint symptoms begin. Up to 80% of people with PsA also develop nail changes: pitting (tiny dents in the nail surface), ridging, crumbling, or separation of the nail from the nail bed. These nail changes are especially common when the nearby fingertip joints are involved.
RA doesn’t cause skin psoriasis or the characteristic nail pitting. It can produce small lumps under the skin called rheumatoid nodules, typically near the elbows or fingers, but these look and feel nothing like psoriatic plaques.
Blood Test Differences
Blood work is one of the clearest ways doctors separate these two conditions. RA is typically “seropositive,” meaning patients test positive for specific immune markers. About 66% of RA patients are positive for rheumatoid factor (RF), and roughly 60% test positive for anti-CCP antibodies, which are proteins the immune system produces when it mistakenly attacks joint tissue.
PsA is usually “seronegative.” In studies, only about 5% of PsA patients tested positive for RF and about 12% for anti-CCP. This seronegative status was actually part of what helped scientists recognize PsA as its own disease rather than just RA happening alongside psoriasis. That said, a small percentage of PsA patients do test positive for these markers, which can complicate diagnosis.
What’s Happening Inside the Joint
Both diseases involve an overactive immune system attacking joint tissue, but the underlying biology differs. RA is driven largely by a branch of the immune system that produces antibodies against the body’s own tissues, leading to intense inflammation of the joint lining. This inflammation erodes bone over time.
PsA involves a different set of immune pathways, particularly those connected to skin inflammation. The immune signaling molecules most active in PsA overlap with those driving psoriasis. This is why PsA can also cause new bone to form near joints, something visible on X-rays as rough, irregular growths at the edges of affected joints. RA, by contrast, is characterized almost exclusively by bone erosion rather than new bone formation. This radiographic difference is another tool doctors use to tell the two apart.
How Each Condition Is Treated
Because the immune pathways differ, treatment strategies diverge in important ways. For RA, the cornerstone medication is methotrexate, a drug that broadly dials down immune activity. It’s typically started early and used long-term, sometimes alongside other immune-suppressing drugs.
For PsA, current guidelines favor a slightly different approach. In treatment-naïve patients with active disease, TNF inhibitors (a class of biologic drugs given by injection or infusion) are preferred as the first-line option. Methotrexate is still recommended, especially when significant skin psoriasis is present, but it sits a step below biologics in the treatment hierarchy. Drugs that target specific immune molecules involved in psoriatic disease, particularly those blocking IL-17 and IL-12/23 pathways, offer additional options that are especially useful for PsA because they address both joint and skin inflammation simultaneously.
Both conditions benefit from early, aggressive treatment. Joint damage from either disease can become permanent if inflammation goes unchecked, and the window for preventing damage is widest in the first year or two after symptoms begin.
Cardiovascular and Metabolic Risks
Both PsA and RA raise your risk of heart disease and metabolic problems well beyond the general population. The most common comorbidity in both groups is abnormal cholesterol levels. Rates of obesity, type 2 diabetes, and high blood pressure are also elevated in both conditions compared to people without inflammatory arthritis.
However, PsA appears to carry a heavier metabolic burden, even early in the disease. Research comparing early-stage PsA and RA patients found that people with PsA had a higher rate of cardiovascular disease and more total comorbidities than their RA counterparts, despite similar body weights. About 75% of early PsA patients had at least one comorbidity, and they were more likely to have multiple conditions stacking up at once. This suggests that the systemic inflammation in psoriatic disease affects blood vessels and metabolism in ways that go beyond what joint inflammation alone would explain.
How Diagnosis Works
There is no single test that definitively confirms either condition. Diagnosis relies on combining the clinical picture with blood work, imaging, and physical exam findings. For PsA, doctors often use a scoring system called the CASPAR criteria. To qualify, a person must have inflammatory joint, spine, or tendon disease plus at least three points from a checklist that includes current or past psoriasis, nail changes typical of psoriasis, a negative rheumatoid factor test, current or past dactylitis, and X-ray evidence of new bone formation near joints.
RA diagnosis leans more heavily on blood markers (RF and anti-CCP), the symmetric pattern of joint swelling, and imaging showing characteristic erosion patterns. In practice, the two conditions can look similar in the early stages, particularly when PsA presents with symmetric joint involvement or when RA patients happen to test seronegative. A personal or family history of psoriasis, the presence of nail changes, or swelling of an entire finger or toe can be the detail that tips the diagnosis toward PsA.